Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.

World J Gastroenterol · 2018 · PMC6010939 · PMID 29930467

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a trend toward significanceno p-value reported

Early response at week 6 was a significant predictive factor of week 14 response/remission in patients with UC, with a trend toward significance in those with CD.

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.